Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6968129 | 0.88 | TP53 (0.53) | TP53SMN1; SMN2TSHRPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL17510088 | 0.86 | TP53 (0.51) | TP53SMN1; SMN2TSHRPOLBALDH1A1 | |
| SCHEMBL29851226 | 0.83 | POLB (0.51) | TP53SMN1; SMN2POLBALDH1A1NPSR1 | |
| SCHEMBL22749233 | 0.82 | SMN1; SMN2 (0.60) | TP53SMN1; SMN2TSHRPOLBALDH1A1 | |
| SCHEMBL18519633 | 0.81 | TP53 (0.54) | TP53SMN1; SMN2TSHRPOLBALDH1A1 | |
| SCHEMBL12437005 | 0.81 | TP53 (0.63) | TP53SMN1; SMN2TSHRPOLBALDH1A1 | |
| SCHEMBL607186 | 0.81 | TP53 (0.63) | TP53SMN1; SMN2TSHRPOLBALDH1A1 | |
| SCHEMBL4682503 | 0.79 | TP53 (0.61) | TP53SMN1; SMN2TSHRPOLBALDH1A1 | |
| SCHEMBL13411078 | 0.79 | EPHX2 (0.53) | TP53SMN1; SMN2TSHRPOLBALDH1A1 | |
| SCHEMBL5398339 | 0.79 | TP53 (0.51) | TP53SMN1; SMN2TSHRPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119855813-A | Pyridazinone-derived compounds for modulating MYC and for medical use | 遗传智力公司 | 2025-04-18 | — | — | CN | claimed |
| EP-3980410-A1 | N-(4-(5-CHLOROPYRIDIN-3-YL)PHENYL)-2-(2-(CYCLOPROPANESULFONAMIDO)PYRIMIDIN-4-YL) BUTANAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Step Pharma S.A.S. (FR) | 2022-04-13 | — | — | EP | claimed |
| WO-2020245665-A1 | N-(4-(5-CHLOROPYRIDIN-3-YL)PHENYL)-2-(2-(CYCLOPROPANESULFONAMIDO)PYRIMIDIN-4-YL) BUTANAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | STEP PHARMA S.A.S. (FR) | 2020-12-10 | — | — | WO | claimed |
| EP-3145912-A1 | BENZENE SULFONAMIDE DERIVATIVES AND THEIR USE AS RORC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-03-29 | — | — | EP | claimed |
| WO-2015177325-A1 | BENZENE SULFONAMIDE DERIVATIVES AND THEIR USE AS RORC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-26 | — | — | WO | claimed |
| US-8288431-B2 | Substituted spiroindolinones | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | claimed |
| EP-2134703-A1 | AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2009-12-23 | — | — | EP | claimed |
| WO-2008110008-A1 | AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-09-18 | — | — | WO | claimed |
| WO-2006130426-A2 | MODULATORS OF CCR-5 ACTIVITY | KEMIA, INC. (US) | 2006-12-07 | — | — | WO | claimed |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | LG CHEM, LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | NIPPON SHINYAKU CO., LTD. (JP) | 2025-06-03 | — | — | US | disclosed |
| WO-2025021182-A1 | CYP11A1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-01-30 | — | — | WO | disclosed |
| EP-4486347-A1 | COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER | Step Pharma S.A.S. (FR) | 2025-01-08 | — | — | EP | disclosed |
| CN-114901653-B | Novel amide derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2024-11-22 | — | — | CN | disclosed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| EP-1878725-A2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20060293354-A1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
| WO-2006130426-A2 | MODULATORS OF CCR-5 ACTIVITY | KEMIA, INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293354-A1 | Pyrimidine derivatives and their use as CB2 modulators | CNR2, CNR1, P2RX3 | TP53 3563/4885SMN1; SMN2 3473/4885TSHR 2969/4885 |
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | PAM, CHRM3, AZI2 | TP53 1770/4885SMN1; SMN2 1008/4885TSHR 3490/4885 |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | DGAT2, DGAT1, DLAT | TP53 4684/4885SMN1; SMN2 4700/4885TSHR 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.